Specific behaviour ‐ agitation · psychosis‐induced aggression or agitation (rapid tranquillisation)
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · people with both severe mental illness and substance misuse
1 finding from 1 review
Subjective well‐being · people with both severe mental illness and substance misuse
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Craving · people with both severe mental illness and substance misuse
1 finding from 1 review
Adherence to antipsychotic medication: number of missed doses, average endpoint data, short term (up to 6 months) · people with both severe mental illness and substance misuse
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: Parkinsonism ‐ average endpoint score (SAS, high = worse) · people with both severe mental illness and substance misuse
1 finding from 1 review
Leaving the study early · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes leaving study early: any reason compared with OLANZAPINE ‒ short‐ and long‐term data (very low certainty).
1 finding from 1 review
Leaving the study early · people with both severe mental illness and substance misuse
RISPERIDONE showed no clear difference in leaving the study early: any reason compared with PERHENAZINE ‒ long‐term data (low certainty).
1 finding from 1 review
Leaving the study early · people with both severe mental illness and substance misuse
RISPERIDONE showed no clear difference in leaving the study early: 1. any reason, long term (>12 months) compared with QUETIAPINE ‒ short‐ and long‐term data (low certainty).
1 finding from 1 review
Leaving the study early · people with both severe mental illness and substance misuse
RISPERIDONE showed no clear difference in leaving the study early: any reason compared with ZIPRASIDONE ‒ long‐term data (> 12 months) (low certainty).
1 finding from 1 review
Substance use: improvement ‒ (at least 20% reduction in use, TLFB scale) · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes substance use: improvement ‒ (at least 20% reduction in use, TLFB… compared with CLOZAPINE ‐ all data short term (very low certainty).
1 finding from 1 review
Subjective well‐being · people with both severe mental illness and substance misuse
1 finding from 1 review
Craving · people with both severe mental illness and substance misuse
1 finding from 1 review
Adherence to antipsychotic medication: discontinued medication · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes adherence to antipsychotic medication: discontinued medication compared with CLOZAPINE ‐ all data short term (very low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes adverse effects. 1. Movement disorders ‐ any extrapyramidal compared with CLOZAPINE ‐ all data short term (very low certainty).
1 finding from 1 review
Leaving the study early · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes leaving the study early ‒ any reason compared with CLOZAPINE ‐ all data short term (very low certainty).
1 finding from 1 review
Mental state: 2. Specific‐ Positive symptoms, total score‐ average endpoint scores (SADS‐C‐PD scale, lower = better) · people with both severe mental illness and substance misuse
1 finding from 1 review
Substance use: 1. Reduction of cannabis use‐change data (number of joints smoked/week) · people with both severe mental illness and substance misuse
1 finding from 1 review
Mental state: No 20% response (as defined by PANSS/BPRS total change) · patients with schizophrenia
It is very uncertain whether RISPERIDONE changes mental state: no clinically significant response in psychotic… compared with PLACEBO (very low certainty).
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
RISPERIDONE may leads to lower leaving the study early ‐ short term (up to 12 weeks) ‐ any reason compared with PLACEBO (low certainty).
1 finding from 1 review